Follow
Linda E. Klumpers
Linda E. Klumpers
Clinical Scientist
Verified email at chdr.nl
Title
Cited by
Cited by
Year
Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone‐induced reduction of adult hippocampal neurogenesis
JL Mayer, L Klumpers, S Maslam, ER De Kloet, M Joels, PJ Lucassen
Journal of neuroendocrinology 18 (8), 629-631, 2006
2262006
A brief background on cannabis: From plant to medical indications
LE Klumpers, DL Thacker
Journal of AOAC International 102 (2), 412-420, 2019
1272019
Manipulating brain connectivity with δ9-tetrahydrocannabinol: a pharmacological resting state FMRI study
LE Klumpers, DM Cole, N Khalili-Mahani, RP Soeter, ET Te Beek, ...
Neuroimage 63 (3), 1701-1711, 2012
1152012
Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ...
British journal of clinical pharmacology 74 (1), 42-53, 2012
922012
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics
JAAC Heuberger, Z Guan, OO Oyetayo, L Klumpers, PD Morrison, ...
Clinical pharmacokinetics 54, 209-219, 2015
892015
Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC
M Tagen, LE Klumpers
British journal of pharmacology 179 (15), 3915-3933, 2022
792022
Peripheral selectivity of the novel cannabinoid receptor antagonist TM 38837 in healthy subjects
LE Klumpers, M Fridberg, ML de Kam, PB Little, NO Jensen, HD Kleinloog, ...
British Journal of Clinical Pharmacology 76 (6), 846-857, 2013
772013
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
British Journal of Clinical Pharmacology 76 (1), 65-77, 2013
312013
Subjective Effects of Ethanol, Morphine, Δ9-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity
D Kleinloog, S Rombouts, R Zoethout, L Klumpers, M Niesters, ...
Brain connectivity 5 (10), 641-648, 2015
152015
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
M Tagen, D Mantuani, L van Heerden, A Holstein, LE Klumpers, ...
Journal of Psychopharmacology 37 (9), 876-890, 2023
72023
Surinabant, a selective CB (1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
Br J Clin Pharmacol 76, 65-77, 2013
52013
Pharmacokinetic/pharmaco–dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ9‐tetrahydrocannabinol …
Z Guan, LE Klumpers, OO Oyetayo, J Heuberger, JMA van Gerven, ...
British Journal of Clinical Pharmacology 81 (4), 713-723, 2016
32016
304 Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
A Monte, A Gorbenko, J Heuberger, KC Cundy, L Klumpers, ...
Annals of Emergency Medicine 82 (4), S133, 2023
12023
Fall 2020 proceedings of the cannabis chemistry subdivision
NB Arora, JL von Salm
ACS Chemical Health & Safety 28 (2), 73-93, 2021
12021
Novel approaches in clinical development of cannabinoid drugs
L Klumpers
Br J Clin Pharmacol 76 (1), 65-77, 2013
12013
First in human trial of an oral tablet with Delta 9-THC (Namisol (R))
LE Klumpers, JMA van Gerven, TL Beumer
EUROPEAN JOURNAL OF NEUROLOGY 17, 493-493, 2010
12010
Pharmacologic resting state-FMRI: effects of cannabis on functional brain connectivity at rest
RP Soeter, LE Klumpers, N Khalili-Mahani, MA van Buchem, ...
Annual Meeting of the Organization for Human Brain Mapping, Barcelona, Spain, 2010
12010
Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design
J Rozanc, LE Klumpers, MA Huestis, M Tagen
Cannabis and Cannabinoid Research, 2024
2024
Pharmacokinetics of Two Nanoemulsion Formulations of Δ8-Tetrahydrocannabinol in Rats
M Tagen, LE Klumpers, A Peshkovsky
AAPS PharmSciTech 24 (8), 239, 2023
2023
380 Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 for Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic …
L Klumpers, A Gorbenko, J Heuberger, K Cundy, GJ Groeneveld, ...
Annals of Emergency Medicine 82 (4), S167, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20